Company Encyclopedia
View More
name
First Trust Multi-Manager Small Cap Opportunities ETF
MMSC.US
News
View More

Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Guardant Health, Inc. is one of the most promising stocks. TheFly reported on December 17 that Mizuho analyst Anthony Petrone maintained an Outperform rating on GH and raised the price target to $120 from $100, reflecting growing confidence in […]

MSN·
US
GH
+1.60%
MSN·
US
GH
+1.60%

Does iRhythm Technologies (IRTC) Asia-Pacific Data Shift Its Competitive Edge in Cardiac Monitoring?

iRhythm Technologies has received strong analyst support and presented new clinical data at Asia-Pacific cardiology conferences, reinforcing its position in cardiac monitoring. Morgan Stanley raised its price target to $205, reflecting optimism about iRhythm's growth potential. Despite positive data, the company faces challenges with ongoing losses and cash burn. Analysts project $1.1 billion revenue and $49.7 million earnings by 2028, with a fair value estimate of $220.60, suggesting a 23% upside. Investors are advised to consider various perspectives due to differing fair value estimates.

Simplywall·
US
IRTC
+3.15%
Simplywall·
US
IRTC
+3.15%

Impinj Unveils New Executive Severance and Change in Control Policy

Impinj Inc. has updated its executive employment agreement with CEO Chris Diorio, Ph.D., to clarify severance and change of control terms. The new policy ensures the greatest after-tax benefit for Dr. Diorio without tax gross-up payments. Additionally, a new Executive Change in Control and Severance Policy has been adopted for key executives, including CFO Cary Baker and Chief Innovation Officer Cathal Phelan. These terms apply to qualifying terminations around a change of control.

Reuters·
US
PI
+2.93%
Reuters·
US
PI
+2.93%

Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 116 Shares of Stock

Guardant Health Director Musa Tariq sold 116 shares at $101.46 each, totaling $11,769.36, reducing his ownership by 1.43%. The sale was disclosed in an SEC filing. Tariq previously sold shares at different prices in October and November. Guardant Health's stock performance shows a market cap of $12.33 billion, with analysts setting new price targets and maintaining a "Moderate Buy" rating. Institutional investors have adjusted their stakes in the company.

Market Beat·
US
GH
+1.60%
Market Beat·
US
GH
+1.60%

Dir Tariq Sells 116 ($11.8K) Of Guardant Health Inc [GH]

Tariq Musa Director of Guardant Health Inc [GH] filed a Form 4 on December 18, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/17/25TransactionPlanned Sale(1) Shares116Price$101.46Value$11,769Ending Holdings: 7,993 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Reuters·
US
GH
+1.60%
Reuters·
US
GH
+1.60%
© 2025 Longbridge｜Disclaimer